These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33413017)

  • 1.
    Fuleihan C
    Am J Law Med; 2020 Nov; 46(4):507-517. PubMed ID: 33413017
    [No Abstract]   [Full Text] [Related]  

  • 2. Expanding Access to Medication Abortions.
    Rubin R
    JAMA; 2022 Jan; 327(2):112-114. PubMed ID: 34935858
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA considering restricted access to "abortion pill".
    Sibbald B
    CMAJ; 2000 Sep; 163(5):586. PubMed ID: 11006770
    [No Abstract]   [Full Text] [Related]  

  • 4. In brief: Mifepristone by mail for pregnancy termination.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):11. PubMed ID: 35134042
    [No Abstract]   [Full Text] [Related]  

  • 5. Time to Reevaluate U.S. Mifepristone Restrictions.
    Henney JE; Gayle HD
    N Engl J Med; 2019 Aug; 381(7):597-598. PubMed ID: 31242357
    [No Abstract]   [Full Text] [Related]  

  • 6. Medication abortion in Canada: a right-to-health perspective.
    Erdman JN; Grenon A; Harrison-Wilson L
    Am J Public Health; 2008 Oct; 98(10):1764-9. PubMed ID: 18703434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mifepristone label laws and trends in use: recent experiences in four US states.
    Sheldon WR; Winikoff B
    Contraception; 2015 Sep; 92(3):182-5. PubMed ID: 26116033
    [No Abstract]   [Full Text] [Related]  

  • 8. Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
    Gomperts RJ; Jelinska K; Davies S; Gemzell-Danielsson K; Kleiverda G
    BJOG; 2008 Aug; 115(9):1171-5; discussion 1175-8. PubMed ID: 18637010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
    Haldane J
    BJOG; 2008 Nov; 115(12):1587-8; author reply 1588-9. PubMed ID: 19054856
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
    Gomperts R; Kleiverda G; Gemzell K; Davies S; Jelinska K
    BJOG; 2008 Nov; 115(12):1578-9. PubMed ID: 19035995
    [No Abstract]   [Full Text] [Related]  

  • 11. From qualified physician to licensed health care professional: the time has come to change mifepristone's label.
    Foster AM; Jackson CB; LaRoche KJ; Simmonds K; Taylor D
    Contraception; 2015 Sep; 92(3):200-2. PubMed ID: 26134281
    [No Abstract]   [Full Text] [Related]  

  • 12. State Restrictions on Mifepristone Access - The Case for Federal Preemption.
    Zettler PJ; Sarpatwari A
    N Engl J Med; 2022 Feb; 386(8):705-707. PubMed ID: 35020981
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.
    Hausknecht RU
    Ann Pharmacother; 2006 Apr; 40(4):785-6; author reply 786. PubMed ID: 16569806
    [No Abstract]   [Full Text] [Related]  

  • 14. Updates to the US Food and Drug Administration Regulations for Mifepristone: Implications for Clinical Practice and Access to Abortion.
    Simmonds KE; Beal MW; Eagen-Torkko MK
    J Midwifery Womens Health; 2017 May; 62(3):348-352. PubMed ID: 28632953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How the pandemic is transforming abortion access.
    Vogel L; Basky G
    CMAJ; 2022 Feb; 194(6):E223. PubMed ID: 35165137
    [No Abstract]   [Full Text] [Related]  

  • 16. "We've got rights and yet we don't have access": Exploring patient experiences accessing medication abortion in Australia.
    LaRoche KJ; Wynn LL; Foster AM
    Contraception; 2020 Apr; 101(4):256-260. PubMed ID: 31927029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Supreme Court's Abortion Exceptionalism - Judicial Deference, Medical Science, and Mifepristone Access.
    Fox D; Cole E
    N Engl J Med; 2021 Jun; 384(24):e94. PubMed ID: 33909959
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.
    Schaff EA; Eisinger SH; Stadalius LS; Franks P; Gore BZ; Poppema S
    Contraception; 1999 Jan; 59(1):1-6. PubMed ID: 10342079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data.
    Cleland K; Smith N
    Contraception; 2015 Sep; 92(3):179-81. PubMed ID: 26093188
    [No Abstract]   [Full Text] [Related]  

  • 20. Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond.
    Raymond EG; Grossman D; Mark A; Upadhyay UD; Dean G; Creinin MD; Coplon L; Perritt J; Atrio JM; Taylor D; Gold M
    Contraception; 2020 Jun; 101(6):361-366. PubMed ID: 32305289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.